Physician profile
Diep Nguyen
NPI 1417140468
$3,228.31
in general payments reported to CMS, 2019-2025
23 companies · $423 in 2025
The $423 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $495 · 2020: $119 · 2021: $623 · 2022: $797 · 2023: $771 · 2025: $423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,194.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $724.65 | 2021-2025 | Minimed 780g |
| Lilly USA, LLC | $331.78 | 2021-2023 | Mounjaro, Trulicity, Jardiance |
| Abbott Laboratories | $328.69 | 2021-2023 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $222.51 | 2022-2025 | Recorlev, Gvoke Hypopen |
| Astrazeneca Pharmaceuticals LP | $184.66 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $170.38 | 2019 | |
| Sanofi-Aventis U.S. LLC | $164.58 | 2019-2023 | |
| Mannkind Corporation | $156.70 | 2022-2023 | Afrezza |
| Esperion Therapeutics, INC. | $155.80 | 2021 | |
| Medtronic Minimed, INC. | $119.28 | 2020 | |
| Merck Sharp & Dohme LLC | $112.08 | 2021-2023 | Verquvo, Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.28 | 2022-2023 | Tradjenta, Jardiance |
| Novo Nordisk INC | $92.31 | 2019-2025 | Ozempic, Rybelsus |
| Tandem Diabetes Care, INC. | $68.64 | 2019 | |
| Horizon Therapeutics Plc | $66.24 | 2021-2023 | Tepezza |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $62.40 | 2019 | |
| Amgen INC. | $37.63 | 2021 | |
| Amryt Pharma Holdings LTD | $36.00 | 2022-2023 | Mycapssa |
| Becton, Dickinson and Company | $24.53 | 2022 | |
| Halozyme INC | $20.99 | 2023 | |
| Antares Pharma, INC. | $17.51 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $16.05 | 2021 | |
| Novartis Pharmaceuticals Corporation | $13.62 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diep Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.